{"id":"neoadjuvant-immunochemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Chemotherapy-related myelosuppression"},{"rate":null,"effect":"Immune-related adverse events (fatigue, rash, pneumonitis)"},{"rate":null,"effect":"Gastrointestinal toxicity"},{"rate":null,"effect":"Cardiac toxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This treatment approach uses chemotherapy to reduce tumor burden and promote immunogenic cell death, while simultaneously activating the immune system through checkpoint inhibitors or other immunotherapeutic agents. Administered before surgery (neoadjuvant setting), it aims to improve pathological complete response rates and enhance long-term survival by priming anti-tumor immunity before definitive surgical intervention.","oneSentence":"Neoadjuvant immunochemotherapy combines chemotherapy with immunotherapy agents to enhance anti-tumor immune responses before surgical resection.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:54.170Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Resectable or locally advanced solid tumors (specific tumor type not specified in available data)"}]},"trialDetails":[{"nctId":"NCT07488624","phase":"","title":"Development and Multicenter Validation of a Novel Bio-Anatomical Staging System for Predicting Survival and Tailoring Adjuvant Therapy in ESCC After Neoadjuvant Chemoimmunotherapy.","status":"COMPLETED","sponsor":"Sichuan University","startDate":"2025-09-01","conditions":"ESCC","enrollment":414},{"nctId":"NCT07468630","phase":"PHASE2","title":"Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-10","conditions":"Colon Adenocarcinoma","enrollment":106},{"nctId":"NCT07457099","phase":"","title":"Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2026-04-01","conditions":"Locally Advanced Oral Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma","enrollment":85},{"nctId":"NCT07452601","phase":"PHASE2","title":"Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2026-02-25","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":90},{"nctId":"NCT07429318","phase":"","title":"Efficacy and Survival Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","enrollment":300},{"nctId":"NCT06656598","phase":"PHASE2","title":"Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2025-11-07","conditions":"Stage III NSCLC","enrollment":152},{"nctId":"NCT06764355","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-07-23","conditions":"ESCC, Total Neoadjuvant Treatment, Pathological Complete Response","enrollment":50},{"nctId":"NCT07182565","phase":"PHASE1, PHASE2","title":"Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-11-18","conditions":"Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy","enrollment":84},{"nctId":"NCT05249959","phase":"PHASE2","title":"Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2022-03-21","conditions":"Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":49},{"nctId":"NCT07309952","phase":"PHASE2","title":"Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Yang Hong","startDate":"2025-12-31","conditions":"Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer","enrollment":28},{"nctId":"NCT06293690","phase":"PHASE2","title":"Toripalimab Combined With SBRT for NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2024-04-15","conditions":"Non-small Lung Cancer","enrollment":40},{"nctId":"NCT06904677","phase":"","title":"Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-05-01","conditions":"Colorectal Cancer (CRC), Neoadjuvant Therapy, Proteomics","enrollment":400},{"nctId":"NCT05189730","phase":"PHASE2","title":"Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2021-07-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":80},{"nctId":"NCT07236320","phase":"NA","title":"Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC","status":"COMPLETED","sponsor":"Yongtao Han","startDate":"2018-03-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":200},{"nctId":"NCT07086469","phase":"PHASE2","title":"Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-20","conditions":"Toripalimab, Surufatinib, Neoadjuvant Immunochemotherapy","enrollment":69},{"nctId":"NCT05675579","phase":"PHASE2","title":"A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-05-23","conditions":"Breast Cancer","enrollment":27},{"nctId":"NCT07181850","phase":"","title":"Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integrating Clinical, Radiomics, and Deep Learning Features","status":"COMPLETED","sponsor":"Nanjing Medical University","startDate":"2019-01-01","conditions":"Esophageal Squamous Cell Carcinoma, Pathological Complete Response","enrollment":363},{"nctId":"NCT07177105","phase":"PHASE2","title":"Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Jianxing He","startDate":"2025-09-10","conditions":"Non Small Cell Lung Cancer","enrollment":118},{"nctId":"NCT07165847","phase":"PHASE2","title":"Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2025-07-23","conditions":"Immunotherapy, Gastric Cancer (GC), Radiotherapy","enrollment":40},{"nctId":"NCT05058404","phase":"PHASE3","title":"Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2021-12-01","conditions":"Follicular Lymphoma","enrollment":605},{"nctId":"NCT07145931","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-20","conditions":"Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy","enrollment":24},{"nctId":"NCT07133958","phase":"","title":"A Bidirectional Observational Clinical Study of NAIC in the Treatment of Tumor Regression Patterns in LA-OSCC and LA-OPSCC","status":"RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2023-07-11","conditions":"Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC)","enrollment":35},{"nctId":"NCT07098104","phase":"","title":"A Benefit Population Atlas of nICT Versus nCT for LAGC","status":"COMPLETED","sponsor":"Cheng Chen","startDate":"2019-11-01","conditions":"Gastric Cancer","enrollment":291},{"nctId":"NCT07090707","phase":"PHASE2","title":"PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006)","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-01","conditions":"HNSCC, PD-1, Radiotherapy","enrollment":50},{"nctId":"NCT07088354","phase":"","title":"Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-03-01","conditions":"Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy, Pathological Complete Response","enrollment":300},{"nctId":"NCT04506554","phase":"PHASE2","title":"A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2020-12-01","conditions":"Muscle-Invasive Bladder Carcinoma","enrollment":81},{"nctId":"NCT07003620","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-06-29","conditions":"Cervical Cancers","enrollment":34},{"nctId":"NCT05319574","phase":"PHASE2","title":"SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-04-24","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":46},{"nctId":"NCT05170503","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-12-29","conditions":"Esophagogastric Junction Adenocarcinoma","enrollment":37},{"nctId":"NCT07015489","phase":"PHASE2","title":"Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-01-01","conditions":"ESCC","enrollment":44},{"nctId":"NCT07011823","phase":"PHASE2","title":"Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC","status":"NOT_YET_RECRUITING","sponsor":"Gangnam Severance Hospital","startDate":"2025-07-16","conditions":"Triple-Negative Breast Neoplasm","enrollment":20},{"nctId":"NCT06446726","phase":"PHASE2","title":"Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-06-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT06598527","phase":"PHASE3","title":"Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study","status":"RECRUITING","sponsor":"Yang Hong","startDate":"2024-10-15","conditions":"Lung Cancer (NSCLC)","enrollment":360},{"nctId":"NCT05870800","phase":"PHASE2","title":"Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2025-06-15","conditions":"Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer","enrollment":28},{"nctId":"NCT06977074","phase":"PHASE2","title":"PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-05-10","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":83},{"nctId":"NCT06982053","phase":"NA","title":"[68Ga]Ga-GZP PET for Early Response Prediction in Colorectal Cancer During Neoadjuvant Therapy","status":"COMPLETED","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-05-06","conditions":"Colorectal Cancer Control and Prevention, Colorectal Cancer Recurrent, Colorectal Cancer Metastatic","enrollment":21},{"nctId":"NCT06288360","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy in PD-L1-negative LACC","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-09-12","conditions":"Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative","enrollment":40},{"nctId":"NCT06258811","phase":"PHASE3","title":"Neoadjuvant Immunochemotherapy for LAOSCC","status":"RECRUITING","sponsor":"Lai-ping Zhong","startDate":"2024-02-20","conditions":"Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma","enrollment":134},{"nctId":"NCT06779435","phase":"","title":"A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-01-01","conditions":"DLBCL","enrollment":400},{"nctId":"NCT06722495","phase":"NA","title":"Efficacy and Safety of a Third-Course of Neoadjuvant Immunochemotherapy Combined With SBRT in Locally Advanced Head and Neck Squamous Cell Carcinoma Patients With Stable Disease After Two Treatment Courses: A Single-Arm Exploratory Study","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-12-24","conditions":"SBRT, Neoadjuvant Immunochemotherapy, LA HNSCC","enrollment":20},{"nctId":"NCT06709885","phase":"PHASE2","title":"HDAC Inhibitor Combination with Chemoimmunotherapy in the Neoadjuvant Treatment of PMMR Locally Advanced Colon Cancer","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2024-10-15","conditions":"Colon Adenocarcinoma","enrollment":100},{"nctId":"NCT06354140","phase":"PHASE2","title":"PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2024-05-07","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":45},{"nctId":"NCT06497322","phase":"NA","title":"Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment","status":"NOT_YET_RECRUITING","sponsor":"University Hospital of Cologne","startDate":"2024-09-01","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":60},{"nctId":"NCT06469060","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2024-06-19","conditions":"Esophageal Cancer","enrollment":34},{"nctId":"NCT06475755","phase":"PHASE2","title":"Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-06-30","conditions":"Non-Small Cell Lung Cancer, Anti Angiogenesis","enrollment":178},{"nctId":"NCT05964101","phase":"PHASE2","title":"Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2023-10-01","conditions":"Neoplasms, Carcinoma, Squamous, Antineoplastic Agents","enrollment":25},{"nctId":"NCT06292052","phase":"","title":"Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2017-01-01","conditions":"Lung Cancer","enrollment":209},{"nctId":"NCT06403878","phase":"PHASE2","title":"Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-05","conditions":"Esophageal Cancer","enrollment":68},{"nctId":"NCT06285058","phase":"","title":"Deep Learning Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-03","conditions":"Deep Learning Model, Pathological Complete Response, Non-small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT06306846","phase":"PHASE2","title":"Neoadjuvant SBRT in Localized Advanced HNSCC","status":"RECRUITING","sponsor":"Jiang Feng","startDate":"2023-10-01","conditions":"Head and Neck Squamous Carcinoma","enrollment":81},{"nctId":"NCT06235164","phase":"","title":"The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Medical University","startDate":"2019-01-01","conditions":"Locally Advanced Gastric Cancer","enrollment":585},{"nctId":"NCT06109402","phase":"PHASE2","title":"Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2023-12-20","conditions":"Stage II-IIIB(N2) Non-small Cell Lung Cancer","enrollment":160},{"nctId":"NCT06103890","phase":"","title":"Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2023-05-22","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":100},{"nctId":"NCT06023797","phase":"","title":"Neoadjuvant Immunochemotherapy for Lung Cancer","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2017-01","conditions":"Lung Cancer","enrollment":83},{"nctId":"NCT06011993","phase":"","title":"Real-world Analysis on the Efficacy and Safety of Neoadjuvant Therapy for Head and Neck Squamous Cell Carcinoma （neoHNSCC）","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-07-19","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT05980715","phase":"PHASE3","title":"PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-01-01","conditions":"HNSCC, Radiotherapy, PD-1","enrollment":324},{"nctId":"NCT05974007","phase":"","title":"Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-01-01","conditions":"Non-Small Cell Lung Cancer","enrollment":1500},{"nctId":"NCT05952661","phase":"","title":"Minimally Residual of Esophageal Cancer 001","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2023-02-22","conditions":"Esophageal Carcinoma, Minimal Residual Disease","enrollment":56},{"nctId":"NCT05429463","phase":"PHASE3","title":"Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-11-11","conditions":"Squamous Cell Non-small Cell Lung Cancer","enrollment":250},{"nctId":"NCT05637580","phase":"","title":"Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC","status":"COMPLETED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2019-05-20","conditions":"Non Small Cell Lung Cancer, Immunotherapy, Chemotherapy","enrollment":110},{"nctId":"NCT05615103","phase":"","title":"The PET-CT Predicting Response to Immunochemotherapy in Esophageal Cancer","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2022-11-08","conditions":"Esophageal Cancer","enrollment":100},{"nctId":"NCT05615129","phase":"","title":"Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting","status":"COMPLETED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2021-10-01","conditions":"Esophagus Cancer","enrollment":350},{"nctId":"NCT05596890","phase":"PHASE2","title":"Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2022-11-30","conditions":"Esophageal Squamous Cell Carcinoma, Patient-reported Outcomes, Immunotherapy","enrollment":50},{"nctId":"NCT04280822","phase":"PHASE3","title":"Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2020-04-21","conditions":"Esophageal Cancer, Surgery, Neoadjuvant Treatment","enrollment":400},{"nctId":"NCT05551767","phase":"PHASE2","title":"Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer","status":"UNKNOWN","sponsor":"City Clinical Oncology Hospital No 1","startDate":"2022-08-30","conditions":"Neck Cancer","enrollment":120},{"nctId":"NCT04459611","phase":"PHASE2","title":"Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-07-01","conditions":"Non-small Cell Lung Cancer","enrollment":60},{"nctId":"NCT05093140","phase":"PHASE2","title":"Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-06-01","conditions":"Primary Extranodal Lymphoma, DLBCL","enrollment":30},{"nctId":"NCT05044728","phase":"PHASE2","title":"Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.","status":"UNKNOWN","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2021-04-01","conditions":"Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma","enrollment":80},{"nctId":"NCT04947241","phase":"PHASE1","title":"Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC","status":"UNKNOWN","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-12-15","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy","enrollment":20},{"nctId":"NCT00801281","phase":"PHASE3","title":"First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.","status":"COMPLETED","sponsor":"Polish Lymphoma Research Group","startDate":"2007-02","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma","enrollment":250},{"nctId":"NCT00073879","phase":"NA","title":"Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2003-04","conditions":"Kidney Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Neoadjuvant immunotherapy","surgery"],"phase":"phase_3","status":"active","brandName":"Neoadjuvant immunochemotherapy","genericName":"Neoadjuvant immunochemotherapy","companyName":"Henan Cancer Hospital","companyId":"henan-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Neoadjuvant immunochemotherapy combines chemotherapy with immunotherapy agents to enhance anti-tumor immune responses before surgical resection. Used for Resectable or locally advanced solid tumors (specific tumor type not specified in available data).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}